InMed Pharmaceuticals Inc (CSE:IN) (OTCMKTS:IMLFF) CEO Eric Adams sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. Based in Vancouver, British Columbia, the pre-clinical stage biopharmaceutical company specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
InMed CEO says 'tremendous potential' for its cannabinoid-based therapy to treat glaucoma
Quick facts: InMed Pharmaceuticals, Inc.
Price: 7.02 CAD
Market Cap: $36.65 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE